TriangleM032 + Pembrolizumab (NCT05084430)
M032 + Pembrolizumab trial for Malignant Glioma (NCT05084430). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with malignant glioma, including glioblastoma, anaplastic astrocytoma and gliosarcoma.
The idea: combine M032, an oncolytic herpes simplex virus that expresses IL-12, with the immunotherapy pembrolizumab, given by vein every three weeks. The first part is in recurrent glioma; a later part includes newly diagnosed glioblastoma.
This phase 1 and 2 study plans 28 patients and first looks at safety and tolerability. At the University of Alabama at Birmingham, James Markert leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.